Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcium/magnesium/potassium/sodium oxybates - Jazz Pharmaceuticals

Next Previous
Drug Profile

Calcium/magnesium/potassium/sodium oxybates - Jazz Pharmaceuticals

Alternative Names: Calcium, magnesium, potassium, and sodium oxybates oral solution; JZP-258; Lower sodium oxybate; LXB; Oxybate mixed salt solution – Jazz Pharmaceuticals; Xywav

Latest Information Update: 04 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jazz Pharmaceuticals plc
  • Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA B receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic hypersomnia; Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cataplexy; Idiopathic hypersomnia; Narcolepsy

Most Recent Events

  • 09 Jul 2026 Jazz Pharmaceuticals initiates the phase III XYRISE trial for Idiopathic hypersomnia in the US (PO) (NCT07625280)
  • 09 Jul 2026 Jazz Pharmaceuticals initiates the phase III XYRISE trial for Narcolepsy in the US (PO) (NCT07625280)
  • 04 Jun 2026 Jazz Pharmaceuticals plans the XYRISE phase III trial for Idiopathic hypersomnia and Narcolepsy (In adults, In the elderly, Treatment experienced) in the US (PO) (NCT07625280)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top